Advanced search
Start date
Betweenand
Related content

PACLITAXEL IN COMBINATION WITH CISPLATIN AS NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA: RETROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY

Grant number: 10/16556-0
Support type:Scholarships in Brazil - Scientific Initiation
Effective date (Start): December 01, 2010
Effective date (End): May 31, 2011
Field of knowledge:Health Sciences - Medicine - Medical Clinics
Principal researcher:Gilberto de Castro Junior
Grantee:Aline Lissa Okita
Home Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil

Abstract

Head and neck squamous cell carcinoma (HNSCC) is usually diagnosed in III/IV stages, locally advanced and/or unresectable with curative intent. These patients are treated with concurrent chemoradiation, which presents better outcomes in comparison with radiation alone. However, chemoradiation is associated with high rates of severe toxicity, and those candidates must present good performance status (PS) and no organ disfunctions in order to tolerate this therapy, not usually found in the majority of HNSCC patients. Induction/neoadjuvant chemotherapy allows the patients to begin radiation therapy with lower tumor burden, less symptomatic, with better PS. In addition, micrometastatic disease is treated earlier. Randomized studies have shown that in patients presenting with metastatic HNSCC, both 5-fluorouracil/cisplatin and paclitaxel/cisplatin (TP) offer equivalent outcomes, and then TP was selected as neoadjuvant regimen for locally advanced HNSCC at Instituto do Câncer do Estado de São Paulo (ICESP), followed by (chemo-)radiation. Here we aim to evaluate efficacy and safety of paclitaxel/cisplatin as neoadjuvant chemotherapy in locally advanced HNSCC treated at ICESP.

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)